ProfileGDS5678 / 1437623_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 64% 63% 61% 63% 65% 68% 62% 62% 62% 63% 62% 67% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9192565
GSM967853U87-EV human glioblastoma xenograft - Control 23.7993464
GSM967854U87-EV human glioblastoma xenograft - Control 33.7545963
GSM967855U87-EV human glioblastoma xenograft - Control 43.590161
GSM967856U87-EV human glioblastoma xenograft - Control 53.7042663
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9536365
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2180468
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7306962
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7246362
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6670762
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7604763
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7054462
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0958167
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7487463